Calliditas Therapeutics AB (CALT) Share Price

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 40.00 High: 40.00

52 Week Range

Low: 15.25 High: 43.00

Liquidityliquidity

Low Moderate High

Fundamentals

  • Market capMarket cap information

    $1,097 Mln

  • P/E RatioP/E Ratio information

    --

  • P/B RatioP/B Ratio information

    103.11

  • Industry P/EIndustry P/E information

    --

  • Debt to EquityDebt to Equity information

    9.2

  • ROEROE information

    -1.57 %

  • ROCEROCE information

    --

  • Div. YieldDiv. Yield information

    0 %

  • Book ValueBook Value information

    --

  • EPSEPS information

    -13.54

9 Years Aggregate

CFO

kr-1,888.33 Mln

EBITDA

kr-2,030.69 Mln

Net Profit

kr-2,183.85 Mln

Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Calliditas Therapeutics AB (CALT)
55.38 -0.87 4.25 118.97 21.29 -- --
BSE Sensex*
0.39 6.40 1.96 7.69 10.43 20.75 10.61
As on 27-Sep-2024  |  *As on 17-Apr-2025
2023
2022
2021
Calliditas Therapeutics AB (CALT)
51.44 -31.34 -26.35
BSE Sensex
18.74 4.44 21.99
BSE Sensex
18.74 4.44 21.99

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

Detailed View
loading...

*All values are in (kr Mln)

loading...

*All values are in (kr Mln)

loading...

*All values are in (kr Mln)

Key Ratios

View All
loading...

loading...

loading...

3Y Avg -- 5Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Shareholding Pattern

Detailed Holdings
loading...
BLAHBLAH

About The Company

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant...  unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.  Read more

  • Chief Executive Officer

    Ms. Renee Aguiar-Lucander

  • Chief Executive Officer

    Ms. Renee Aguiar-Lucander

  • Headquarters

    Stockholm

  • Website

    https://www.calliditas.se

Edit peer-selector-edit
loading...
loading...

FAQs for Calliditas Therapeutics AB (CALT)

The total asset value of Calliditas Therapeutics AB (CALT) stood at $ 2,177 Mln as on 30-Jun-24

The share price of Calliditas Therapeutics AB (CALT) is $40.00 (NASDAQ) as of 27-Sep-2024 09:30 EDT. Calliditas Therapeutics AB (CALT) has given a return of 21.29% in the last 3 years.

Calliditas Therapeutics AB (CALT) has a market capitalisation of $ 1,097 Mln as on 27-Sep-2024. As per Value Research classification, it is a company.

The P/B ratio of Calliditas Therapeutics AB (CALT) is 103.11 times as on 27-Sep-2024, a 4403% premium to its peers’ median range of 2.29 times.

Since, TTM earnings of Calliditas Therapeutics AB (CALT) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Calliditas Therapeutics AB (CALT) and enter the required number of quantities and click on buy to purchase the shares of Calliditas Therapeutics AB (CALT).

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. As of September 13, 2024, Calliditas Therapeutics AB (publ) operates as a subsidiary of Asahi Kasei Corporation.

The CEO & director of Ms. Renee Aguiar-Lucander. is Calliditas Therapeutics AB (CALT), and CFO & Sr. VP is Ms. Renee Aguiar-Lucander.

There is no promoter pledging in Calliditas Therapeutics AB (CALT).

Some of the close peers are:

Company Market Cap($ Mln)
Calliditas Therapeutics AB (CALT) Ratios
Return on equity(%)
-217.56
Operating margin(%)
-23.02
Net Margin(%)
-30
Dividend yield(%)
--

No, TTM profit after tax of Calliditas Therapeutics AB (CALT) was $-168 Mln.